NCT07386704 2026-02-04
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Peking University First Hospital
Phase 2 Enrolling by invitation
Clinical Trials
14 trialsNCT07302841 2025-12-24
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Not yet recruiting
NCT07271823 2025-12-09
Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer
Zhejiang Cancer Hospital
Active not recruiting
NCT06605430 2025-07-29
CanPan-C
HealthPartners Institute
Phase 2 Recruiting
NCT06937996 2025-06-17
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
Englewood Hospital and Medical Center
Recruiting
NCT06478459 2024-12-27
Endoscopic Ultrasound (EUS) Intratumoral Injection of CAR-NK Cells in the Treatment of Advanced Pancreatic Cancer
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT06503497 2024-12-27
A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04156087 2024-09-19
MIMIPAC
University Hospital, Gasthuisberg
Phase 2 Completed
NCT06387368 2024-04-29
Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer
Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT05424159 2023-12-07
Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
Shanghai Proton and Heavy Ion Center
Phase NA Recruiting
NCT05802485 2023-04-06
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
Institut Paoli-Calmettes
Phase NA Not yet recruiting
NCT05047991 2021-09-17
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT03165591 2019-08-30
V3-P
Immunitor LLC
Phase 1/2 Unknown
NCT03964064 2019-07-19
Ckvssip
Peking University Third Hospital
Phase NA Unknown